NCT03478280 - Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 15, 2018

Primary Completion Date

March 15, 2020

Study Completion Date

March 15, 2020

Conditions

Psoriasis

Interventions

DRUG

Brodalumab

Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period

DRUG

Placebos

Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period

Trial Locations (1)

8200

RECRUITING

Aarhus University Hospital, Aarhus